Koh Y - Search Results

1

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Among authors: koh y. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.

2

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH, Heo DS. Koh Y, et al. Ann Oncol. 2009 Aug;20(8):1414-9. doi: 10.1093/annonc/mdp002. Epub 2009 May 25. Ann Oncol. 2009. PMID: 19468031 Free article.

3

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.

Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party. Koh Y, et al. Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25. Ann Hematol. 2010. PMID: 19705118

4

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Koh Y, Lee SY, Kim I, Kwon JH, Yoon SS, Park S, Chung MH, Suh SY, Kim KS, Kim HS. Koh Y, et al. Cancer Chemother Pharmacol. 2014 Sep;74(3):653-7. doi: 10.1007/s00280-014-2555-0. Epub 2014 Aug 6. Cancer Chemother Pharmacol. 2014. PMID: 25096796

5

Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Kim JW, Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I. Kim JW, et al. Among authors: koh y. J Clin Virol. 2015 Dec;73:64-69. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24. J Clin Virol. 2015. PMID: 26546878

6

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.

Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK; Korean Multiple Myeloma Working Party. Kim SJ, et al. Among authors: koh y. Blood Res. 2016 Sep;51(3):193-199. doi: 10.5045/br.2016.51.3.193. Epub 2016 Sep 23. Blood Res. 2016. PMID: 27722131 Free PMC article.

7

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.

Shin J, Koh Y, Youk J, Kim M, Kim BS, Choi CW, Sung HJ, Park Y, Yoon SS, Kim I. Shin J, et al. Among authors: koh y. Korean J Intern Med. 2017 Jul;32(4):722-730. doi: 10.3904/kjim.2016.256. Epub 2017 Jun 26. Korean J Intern Med. 2017. PMID: 28651310 Free PMC article.

8

Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.

Park SS, Eom HS, Kim JS, Koh Y, Choi CW, Lee JJ, Kim K, Suh C, Lee JH, Min CK; Korean Multiple Myeloma Working Party. Park SS, et al. Among authors: koh y. Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177. Jpn J Clin Oncol. 2019. PMID: 30476124

9

A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).

Park BB, Kim WS, Suh C, Hong JY, Yang DH, Lee WS, Do YR, Koh YI, Won JH, Kim MK, Jo JC, Hyun SY, Kim JA, Oh YH, Lee SS. Park BB, et al. Leuk Lymphoma. 2019 Dec;60(13):3251-3257. doi: 10.1080/10428194.2019.1622100. Epub 2019 Jun 6. Leuk Lymphoma. 2019. PMID: 31170847 Clinical Trial.

10

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).

Byun JM, Yoon SS, Koh Y, Min CK, Lee JH, Jo J, Park H, Lee J, Kang KW, Lee Y; and the Korean Multiple Myeloma Working Party (KMMWP). Byun JM, et al. Among authors: koh y. Ther Adv Hematol. 2020 May 12;11:2040620720921046. doi: 10.1177/2040620720921046. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32523660 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,117 results

Search Page